

Special Issue

Recent Advances in Antiviral and Antibacterial Drugs

Message from the Guest Editor

The COVID-19 pandemic inspired more research on global infectious disease, particularly in the field of antiviral drug discovery. Such efforts have led to rapid innovations in diagnosis, vaccine development, direct-acting antivirals, and therapeutic strategies. However, many challenges still exist, including viral evolution, therapeutic resistance, and the escalating threat of antimicrobial resistance (AMR). Learning from these challenges and seeking novel discoveries in this field are critical to help the world prepare for future outbreaks. This Special Issue aims to address progress in antimicrobial research and the critical insights gained in the post-pandemic era. We welcome the submission of original research articles, reviews, and perspectives that explore recent advances in this field. Topics of interest include, but are not limited to, the following:

- Novel antiviral agents and therapeutic targets.
- Innovative antimicrobial strategies to combat AMR.
- Advances in rapid diagnostics and surveillance for viral and bacterial pathogens.
- The analysis of clinical trial design and outcomes for pandemic-era therapeutics.
- The role of host-directed therapies in treating infectious diseases.

Guest Editor

Dr. Mohammad Anwar Hossain

Eshelman Innovation, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/252746

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).